Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration
The collaboration leverages Remix’s REMaster™ platform to discover novel drugs for a diverse range of target classes
Remix is eligible to receive up to $1 billion in milestone payments and royalties
Related news for (RHHBY)
- Cancer Breakthroughs, Blockchain Bets, and Biotech Boldness
- Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates
- 24/7 Market News- Sangamo Therapeutics Entered Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech
- Exploring New Frontiers in Food Allergy Treatments: Market Set for $14B Growth
- New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions